MX2020001732A - Tratamiento de las afecciones del sistema nervioso central. - Google Patents

Tratamiento de las afecciones del sistema nervioso central.

Info

Publication number
MX2020001732A
MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A
Authority
MX
Mexico
Prior art keywords
treatment
cns conditions
mammal
cns
conditions
Prior art date
Application number
MX2020001732A
Other languages
English (en)
Inventor
Nishi Toshiya
Kondo Shinichi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020001732A publication Critical patent/MX2020001732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Los aspectos de la presente invención se refieren a un método para tratar una encefalopatía epiléptica en un mamífero en necesidad del mismo, que comprende administrar para al mamífero una composición que comprende una cantidad eficaz de (4-bencil-4-hidroxipiperidin-1-il) (2,4´-bipiridina-3-il)metanona o una sal farmacéuticamente aceptable de la misma.
MX2020001732A 2017-08-31 2018-08-30 Tratamiento de las afecciones del sistema nervioso central. MX2020001732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Publications (1)

Publication Number Publication Date
MX2020001732A true MX2020001732A (es) 2020-03-20

Family

ID=63722720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001732A MX2020001732A (es) 2017-08-31 2018-08-30 Tratamiento de las afecciones del sistema nervioso central.

Country Status (8)

Country Link
US (3) US11285139B2 (es)
EP (1) EP3675852A1 (es)
JP (2) JP7196157B2 (es)
KR (1) KR102680786B1 (es)
CN (2) CN111065394B (es)
CA (1) CA3073925A1 (es)
MX (1) MX2020001732A (es)
WO (1) WO2019045121A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2017005002A (es) 2014-10-16 2018-01-23 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc.
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
AR109393A1 (es) 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
GB2597285A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007257B1 (pt) 2011-10-07 2023-04-25 Takeda Pharmaceutical Company Limited Composto 1-arilcarbonil-4-oxi-piperidina
SG11201504516PA (en) 2012-12-11 2015-07-30 Takeda Pharmaceutical Heterocyclic compound
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017065287A1 (ja) 2015-10-16 2017-04-20 武田薬品工業株式会社 複素環化合物の製造方法

Also Published As

Publication number Publication date
KR102680786B1 (ko) 2024-07-02
US20200306238A1 (en) 2020-10-01
US20220168294A1 (en) 2022-06-02
CN111065394B (zh) 2023-03-31
JP7196157B2 (ja) 2022-12-26
JP2023027267A (ja) 2023-03-01
JP2020532508A (ja) 2020-11-12
KR20200046022A (ko) 2020-05-06
CA3073925A1 (en) 2019-03-07
US11285139B2 (en) 2022-03-29
WO2019045121A1 (en) 2019-03-07
CN116370475A (zh) 2023-07-04
JP7469445B2 (ja) 2024-04-16
EP3675852A1 (en) 2020-07-08
CN111065394A (zh) 2020-04-24
US20230087903A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
PH12020500286A1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
PH12017500493A1 (en) Combination therapy
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
NZ738672A (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2016008968A (es) Compuestos organicos.
MX2018001684A (es) Metodo de curacion de heridas.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019014784A (es) Tratamiento para la migra?a.
AR099416A1 (es) Terapia combinada para la hipertensión resistente
MX2019004200A (es) Terapia de combinacion.
EA201990413A1 (ru) Способ лечения печеночной энцефалопатии